B4
B4V.F Arcticzymes Technologies ASA
- Market cap
- EUR 108M
- P/E
- 105.5x
- P/B
- 3.15x
- ROE
- 2.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is B4V.F undervalued?
Graham numberThe Graham number of Arcticzymes Technologies ASA cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Arcticzymes Technologies ASA fundamental analysis
No fundamental analysis for Arcticzymes Technologies ASA yet.
Arcticzymes Technologies ASA stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Arcticzymes Technologies ASA
ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, in vitro diagnostics, and biomanufacturing. The company offers shrimp alkaline phosphatase; cod UNG for use in viral and other molecular diagnostic assays for the removal of contaminating dU-DNA; salt active nucleases for the removal of nucleic acids during manufacturing of viral vectors, recombinant proteins, and other reagents…
Full company profileArcticzymes Technologies ASA financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Arcticzymes Technologies ASA annual financial statements (NOK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 71.9M | 66.7M | 66.8M | 77.2M | 93.4M | 128M | 137M | 119M | 104M | 113M | 129M |
| Gross Profit | 45.2M | 44.8M | 47.4M | 58.3M | 92.3M | 124M | 132M | 113M | 98.4M | 108M | 121M |
| Operating Income | -20.2M | -24.9M | -14.2M | -5.76M | 42.8M | 58.4M | 36.5M | 15.7M | -1.44M | 2.63M | 7.01M |
| EBITDA | - | -22.1M | -11.9M | -46.0K | 53.0M | 62.9M | 47.7M | 31.6M | 17.5M | 21.4M | 16.1M |
| Net Income | -20.5M | -24.9M | -14.0M | -6.39M | 83.1M | 46.4M | 32.9M | 19.4M | 8.47M | 9.74M | 9.60M |
| EPS | - | -0.57 | -0.29 | -0.13 | 1.72 | 0.92 | 0.65 | 0.38 | 0.17 | 0.19 | 0.19 |
| Balance Sheet | |||||||||||
| Total Assets | 85.8M | 61.7M | 68.0M | 77.6M | 222M | 284M | 319M | 339M | 344M | 361M | 384M |
| Total Liabilities | 17.7M | 16.9M | 14.1M | 31.1M | 25.6M | 39.3M | 34.3M | 30.0M | 20.9M | 22.9M | 34.2M |
| Shareholders' Equity | 67.5M | 44.1M | 53.0M | 45.1M | 194M | 245M | 285M | 309M | 323M | 338M | 350M |
| Cash & Short-term Investments | 56.2M | 28.6M | 31.0M | 29.6M | 139M | 199M | 242M | 179M | 171M | 188M | 192M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -19.3M | -22.1M | -15.2M | 3.97M | 46.7M | 75.0M | 58.1M | 24.4M | 1.66M | 25.8M | 17.3M |
| Capital Expenditure | 1.35M | 2.63M | 1.27M | 688K | 1.91M | 10.0M | 4.81M | 21.0M | 9.52M | 3.64M | 8.28M |
| Free Cash Flow | - | -27.1M | -21.0M | 2.87M | 45.0M | 63.4M | 45.7M | 3.42M | -7.86M | 22.2M | 9.02M |
| Ratios | |||||||||||
| ROE | -30.3% | -56.6% | -26.4% | -14.1% | 42.8% | 18.9% | 11.5% | 6.3% | 2.6% | 2.9% | 2.7% |
| ROA | -23.9% | -40.4% | -20.6% | -8.2% | 37.5% | 16.3% | 10.3% | 5.7% | 2.5% | 2.7% | 2.5% |
| Net Profit Margin | -28.5% | -37.4% | -21.0% | -8.3% | 88.9% | 36.2% | 24.0% | 16.3% | 8.1% | 8.6% | 7.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Arcticzymes Technologies ASA dividends
Arcticzymes Technologies ASA has not paid dividends in the last 9 fiscal years.
Who owns Arcticzymes Technologies ASA
- Insiders 17.41%
- Institutions 13.81%
- Public & others 68.78%
- Shares outstanding 51.1M
- Free float 37.6M
Arcticzymes Technologies ASA company profile
- Company name
- Arcticzymes Technologies ASA
- Ticker
- B4V.F
- ISIN
- NO0010014632
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 50
- Fiscal year end
- December
- Address
- Sykehusveien 23, Tromsø, Norway, 9294
- Phone
- 47 77 64 89 00
- Website
- arcticzymes.com
About Arcticzymes Technologies ASA
ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, in vitro diagnostics, and biomanufacturing. The company offers shrimp alkaline phosphatase; cod UNG for use in viral and other molecular diagnostic assays for the removal of contaminating dU-DNA; salt active nucleases for the removal of nucleic acids during manufacturing of viral vectors, recombinant proteins, and other reagents; and double-strand specific DNases and derived kits for the removal of double stranded DNA. It also provides DNA/RNA polymerases for technology development for life science, molecular diagnostics, NGS, and synthetic biology; proteinase for microbiological diagnostics and liquid biopsies; and ligases for joining nucleic acids. The company serves the molecular tools market, and biomanufacturing markets. It operates in Norway, Germany, Lithuania, France, Italy, the United Kingdom, rest of Europe, the United States, and internationally. The company was formerly known as Biotec Pharmacon ASA and changed its name to ArcticZymes Technologies ASA in June 2020. ArcticZymes Technologies ASA was founded in 1990 and is headquartered in Tromsø, Norway.
Arcticzymes Technologies ASA management
5- Mr. Michael Benjamin AkohChief Executive Officer · born 1973
- Mr. Borge SorvollChief Financial Officer · born 1975
- Dr. Marit Sjo LorentzenVice President of Operations · born 1968
- Mr. Paul Blackburn Ph.D.C.C.O · born 1974
- Mr. Steve DeyGlobal Director of Product Management & Marketing